SCI-RSC Targeting Protein Degradation 5

Synopsis

One of the most exciting new therapeutic modalities to emerge in the 21st century has been Targeted Protein Degradation (TPD). In 2021, the Targeted Protein Degradation Market size was valued at USD 400.5 million and is poised to grow from USD 507.0 million in 2022 to USD 3,300.0 million by 2030 and so has attracted interest from academia, non-profit organisations through to CROs and small and large pharma.

This multidisciplinary meeting aims to present the latest developments in the design, biology, chemistry and ADME in TPD within the general themes of PROTACS (including non-oncology targets), Molecular Glues and non-PROTAC degraders. We aim to highlight the newest in enabling technologies such as computational techniques, Direct to Biology, HT synthesis (click, photochemistry etc) and structural biology methods.

---

Attendees

The meeting aims is targeted at academic and industrial scientists engaged in all aspects of research into the ubiquitin proteasome pathway and those interested in broadening their knowledge in this rapidly expanding field.

---

Programme

The full programme will be confirmed in due course. Please see the webpage.

---

Call for abstracts

For details on abstract submission, please see the webpage.

---

Exhibition and sponsorship

For further information and prices, please email events@hg3.co.uk

 

---

Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.

---

Venue and Contact

---

---

Organising committee

Sean Bew, UEA
A Ganesan, University of East Anglia
Katherine Jones, Charles River 
Jayshree Mistry
Suzanne O’Connor, University of Dundee
Hannah Woodward, MSD 

---